RudaCure CEO Yongho Kim and BD team member Harris Hasrol participated in the University of Utah technology briefing held from September 25 to 29, where they promoted the company's technologies to U.S.-based venture capitalists and conducted investment meetings.
According to their report, there was strong interest from local attendees in the chronic pain treatment, as well as significant attention toward the dry eye disease treatment and corneal damage recovery agent currently in clinical preparation. The reception indicated an active desire to move forward with joint research and investment opportunities.
It is expected that the investor presentation taking place in San Francisco from October 2nd onward will also yield positive results.
Following the San Francisco investor presentation, BD team member Harris Hasrol will travel to Singapore to attend the Shinhan Square Bridge-organized investor roadshow (October 10–13), where he will present the company's technologies to Asian investors. He will then travel to Europe to attend Bio Europe, where he plans to discuss specific details of technology transfer with Ceva, with whom RudaCure is currently in discussions regarding veterinary drug development.